Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Opal

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
Critical Care (London, England)|March 17, 2009
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaPierre-François Laterre, Steven M Opal, Edward Abraham, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsisAbdullah Chahin, Steven M Opal, Jorge Zorzopulos, et al.
Shock (Augusta, Ga.)|June 5, 2010
Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infectionSteven M Opal, Yow-Pin Lim, Patricia Cristofaro, et al.
Vaccine|October 25, 2003
Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjectsAlan S Cross, Steven M Opal, John E Palardy, et al.
Thrombosis and Haemostasis|May 6, 2006
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparinJohannes N Hoffmann, Christian J Wiedermann, Mathias Juers, et al.
Critical Care Medicine|November 20, 2015
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III TrialBita Shakoory, Joseph A Carcillo, W Winn Chatham, et al.
Innate Immunity|April 16, 2021
A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsisAlan S Cross, Steven M Opal, John E Palardy, et al.
EMBO Molecular Medicine|May 19, 2011
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsisSarah L Tressel, Nicole C Kaneider, Shogo Kasuda, et al.
The Journal of Infectious Diseases|December 20, 2005
The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levelsAnand Kumar, Cameron Haery, Bhanu Paladugu, et al.
Respiratory Medicine|April 19, 2015
Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA studyTobias Welte, R Phillip Dellinger, Henning Ebelt, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
Critical Care (London, England)|March 17, 2009
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaPierre-François Laterre, Steven M Opal, Edward Abraham, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsisAbdullah Chahin, Steven M Opal, Jorge Zorzopulos, et al.
Shock (Augusta, Ga.)|June 5, 2010
Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infectionSteven M Opal, Yow-Pin Lim, Patricia Cristofaro, et al.
Vaccine|October 25, 2003
Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjectsAlan S Cross, Steven M Opal, John E Palardy, et al.
Thrombosis and Haemostasis|May 6, 2006
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparinJohannes N Hoffmann, Christian J Wiedermann, Mathias Juers, et al.
Critical Care Medicine|November 20, 2015
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III TrialBita Shakoory, Joseph A Carcillo, W Winn Chatham, et al.
Innate Immunity|April 16, 2021
A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsisAlan S Cross, Steven M Opal, John E Palardy, et al.
EMBO Molecular Medicine|May 19, 2011
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsisSarah L Tressel, Nicole C Kaneider, Shogo Kasuda, et al.
The Journal of Infectious Diseases|December 20, 2005
The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levelsAnand Kumar, Cameron Haery, Bhanu Paladugu, et al.
Respiratory Medicine|April 19, 2015
Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA studyTobias Welte, R Phillip Dellinger, Henning Ebelt, et al.
Pageof 17